

ozden zen Altundag

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7275216/ozden-ozen-altundag-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125
papers

2,810
citations

15
h-index

52
g-index

136
ext. papers

3,745
ext. citations

5.1
avg, IF

3.96
L-index

#	Paper	IF	Citations
125	Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging. <i>Journal of Obstetrics and Gynaecology</i> , 2021 , 41, 414-420	1.3	1
124	Survival impact of number of removed para-aortic lymph nodes in stage I epithelial ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 1	2.5	0
123	Single-Center Experience of Recurrence Patterns and Survival Analyses of Patients With Hepatocellular Carcinoma and Liver Transplant. <i>Experimental and Clinical Transplantation</i> , 2020 , 18, 201-205	0.8	1
122	Posttransplant Malignancies in Adult Renal and Hepatic Transplant Patients. <i>Experimental and Clinical Transplantation</i> , 2020 , 18, 470-473	0.8	0
121	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 1819-1830	40	1272
120	Durvalumab in Stage III Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 869-879	9.2	21
119	Posttransplant Malignancies in Adult Renal and Hepatic Transplant Patients. <i>Transplantation</i> , 2018 , 102, S225	1.8	
118	The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2017 , 296, 989-995	2.5	24
117	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016 , 27, 16-41	10.3	497
116	Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 639-40	2.2	1
115	Triple negative breast cancer: Demographic and clinicopathological properties.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e12572-e12572	2.2	
114	Combined versus sequential anthracycline and taxane adjuvant regimens in triple negative breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e12578-e12578	2.2	
113	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 2-30	3.5	358
112	Trastuzumab in metastatic breast cancer after complete remission: How long is enough?. <i>Medical Oncology</i> , 2015 , 32, 211	3.7	2
111	ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2015 , 117, 559-81	5.3	131
110	The relationship between thyroid volume and malignant thyroid disease. <i>Medical Oncology</i> , 2014 , 31, 814	3.7	7
109	Paraaortic Lymph Node Dissection in Endometrial Cancer; Is It Necessary?. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2014 , 279-280	1.8	

108	Good outcomes of patients with stage IB endometrial cancer with surgery alone. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014 , 15, 3891-3	1.7	8
107	Response rates of taxane rechallenge in metastatic breast cancer patients, previously treated with adjuvant taxanes.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1073-1073	2.2	1
106	Is there any correlation between molecular subtypes and blood groups in breast cancer?. <i>Journal of Clinical Oncology</i> , 2014 , 32, e11554-e11554	2.2	
105	The relationship between glucose metabolism disorders and malignant thyroid disease. <i>International Journal of Clinical Oncology</i> , 2013 , 18, 585-9	4.2	8
104	Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2013 , 131, 546-50	4.9	20
103	Tiroid Kanserinde Tirozin Kinaz İnhibitörleri: Axl/Gas6 Yolağizli Bir Hedef Olabilir mi?. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2013 , 23, 207-212	1.8	
102	Impact of treatment strategies on local control and survival in uterine carcinosarcomas in Turkey. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013 , 14, 2959-62	1.7	2
101	A Turkish Gynecologic Oncology Group study of fertility-sparing treatment for early-stage endometrial cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2012 , 119, 270-3	4	23
100	Oxaliplatin-Induced Immune Thrombocytopenia in a Patient with Colon Cancer. <i>American Surgeon</i> , 2011 , 77, 9-9	0.8	5
99	Management of kikuchi-fujimoto disease using glucocorticoid: a case report. <i>Case Reports in Medicine</i> , 2011 , 2011, 230840	0.7	15
98	Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: Baskent University experience.. <i>Journal of Clinical Oncology</i> , 2011 , 29, e16001-e16001	2.2	2
97	Emerging drugs in endometrial cancers. <i>Expert Opinion on Emerging Drugs</i> , 2010 , 15, 557-68	3.7	6
96	Preoperative Doppler sonography for prevention of perioperative stroke in head and neck cancer patients undergoing neck dissection: is it beneficial?. <i>Journal of Clinical Ultrasound</i> , 2007 , 35, 38-9	1	9
95	Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 141-6	8.9	28
94	Angiotensin 1-7 and risk for breast cancer recurrence. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 58, 283; author reply 284	3.5	1
93	Inactivation of E-cadherin and less sensitivity of lobular breast carcinoma cells to chemotherapy. <i>Breast</i> , 2006 , 15, 300	3.6	7
92	Coffee and breast cancer risk. <i>International Journal of Cancer</i> , 2006 , 118, 1852	7.5	0
91	Recent findings for anti-metastatic potential of heparin. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2006 , 12, 376-7	3.3	1

90	Weekly paclitaxel may improve locoregional recurrence by decreasing interstitial fluid pressure in operable node-positive breast cancer patients. <i>Medical Hypotheses</i> , 2006 , 66, 211-2	3.8	
89	Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor. <i>Medical Hypotheses</i> , 2006 , 66, 444-5	3.8	
88	Increased cabbage intake may inhibit metastatic and invasive capacity of breast cancer cells by inhibiting CXCL12(SDF-1 alpha)/CXCR4. <i>Medical Hypotheses</i> , 2006 , 66, 672	3.8	1
87	Neoadjuvant chemotherapy with weekly paclitaxel in breast cancer patients may increase release of cancer cells into circulation by decreasing interstitial fluid pressure. <i>Medical Hypotheses</i> , 2006 , 66, 857-8	3.8	
86	Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors. <i>Medical Hypotheses</i> , 2006 , 66, 1045-6	3.8	2
85	Aromatase inhibitors may be effective in the management of advanced hepatocellular carcinoma. <i>Medical Hypotheses</i> , 2006 , 66, 1257	3.8	2
84	Bisphosphonate use for osteoporosis in postmenopausal women may inhibit occurrence of malignant microcalcification in breast tissue. <i>Medical Hypotheses</i> , 2006 , 67, 202-3	3.8	4
83	Low incidence of mammographically detected microcalcification in breast cancer patients with lobular histology may be attributed to low levels of osteopontin. <i>Medical Hypotheses</i> , 2006 , 67, 421-2	3.8	
82	Is it feasible to adjust bisphosphonate dose according to bone mineral density value in postmenopausal breast cancer patients with bone metastases?. <i>Medical Hypotheses</i> , 2006 , 66, 1254-5	3.8	
81	Lactation, galactorrhea, and timing of reduction mammoplasty. <i>Plastic and Reconstructive Surgery</i> , 2006 , 117, 701	2.7	
80	Possible association between nanobacteria and malignant microcalcifications in breast cancer. <i>Breast Journal</i> , 2006 , 12, 287	1.2	11
79	Tobacco smoking and breast cancer. <i>Breast Journal</i> , 2006 , 12, 396-7	1.2	5
78	Overcoming trastuzumab resistance with nordihydroguaiaretic acid?. <i>Breast Cancer Research and Treatment</i> , 2006 , 96, 301	4.4	
77	Which is better in neoadjuvant treatment of breast cancer? Taxane followed by anthracycline or vice versa. <i>Breast Cancer Research and Treatment</i> , 2006 , 97, 221	4.4	
76	Human papilloma virus and breast cancer. <i>Journal of Clinical Virology</i> , 2005 , 33, 179	14.5	
75	Insulinlike growth factor-1 receptor: predictive factor in breast cancer patients treated with trastuzumab?. <i>Human Pathology</i> , 2005 , 36, 448-9; author reply 449	3.7	3
74	SRL172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients. <i>Medical Hypotheses</i> , 2005 , 64, 248-51	3.8	3
73	Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients. <i>Medical Hypotheses</i> , 2005 , 64, 1162-5	3.8	5

72	Bisphosphonates may inhibit development of atherosclerosis formation through its bactericidal effect on nanobacteria. <i>Medical Hypotheses</i> , 2005 , 64, 1239-40	3.8	10
71	Are all prognostic factors changing with time in breast cancer? - New proposal for classification of prognostic factors as time-dependent and time-independent. <i>Medical Hypotheses</i> , 2005 , 65, 413-4	3.8	
70	Pure and mixed hormone receptor positive breast tumors: are they different from therapeutic point of view?. <i>Medical Hypotheses</i> , 2005 , 65, 194	3.8	
69	Acidosis might make breast cancer cells more susceptible to metastasize by shifting CXCL12 monomer-dimer equilibrium to monomeric state. <i>Medical Hypotheses</i> , 2005 , 65, 626-7	3.8	
68	Imatinib may be useful in the management of patients with glioblastoma. <i>Medical Hypotheses</i> , 2005 , 65, 1205-6	3.8	2
67	Phenytoin may increase the efficacy of temozolomide by methylating DNA-repair enzyme, O6-methylguanine-DNA methyltransferase in patients with glioblastoma. <i>Medical Hypotheses</i> , 2005 , 65, 819-20	3.8	
66	Does paclitaxel decrease the interstitial fluid pressure and improve oxygenation in breast cancer in a schedule-dependent fashion?. <i>Medical Hypotheses</i> , 2005 , 65, 1002-3	3.8	
65	Gender differences in the dihydropyrimidine dehydrogenase expression may contribute to higher toxicity in women treated with 5-fluorouracil therapy. <i>Medical Hypotheses</i> , 2005 , 65, 1196	3.8	0
64	Tamoxifen may increase insulin requirement in breast cancer patients with type 1 diabetes mellitus through its agonistic activity on splenic endothelial cells and inhibitory effect on pancreatic beta cells. <i>Medical Hypotheses</i> , 2005 , 65, 815-6	3.8	1
63	Association between obesity and multiple myeloma in postmenopausal women may be attributed to increased aromatization of androgen in adipose tissue. <i>Medical Hypotheses</i> , 2005 , 65, 1001-2	3.8	12
62	Incidence of mandibular osteoradionecrosis may be low in head and neck cancer patients treated with concurrent radiation and weekly paclitaxel. <i>Medical Hypotheses</i> , 2005 , 65, 994-5	3.8	2
61	Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. <i>Urology</i> , 2005 , 65, 211-2; author reply 212	1.6	1
60	Cytokines and chemokines as predictive markers in non-small cell lung cancer patients with brain metastases. <i>Lung Cancer</i> , 2005 , 47, 291-2	5.9	5
59	Smoking status and adenocarcinoma histology may explain an improved survival in the female non-small cell lung cancer patients. <i>Lung Cancer</i> , 2005 , 49, 137; author reply 139	5.9	
58	HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients. <i>Lung Cancer</i> , 2005 , 49, 279-80	5.9	3
57	Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer. <i>Lung Cancer</i> , 2005 , 49, 429	5.9	1
56	Association between epidermal growth factor receptor mutation and improved survival in never-smokers with primary adenocarcinoma of the lung. <i>Chest</i> , 2005 , 127, 2292	5.3	2
55	Closure of large scalp defects by modified Gillies triple scalp flaps in patients with scalp tumors. <i>Plastic and Reconstructive Surgery</i> , 2005 , 116, 1813-4	2.7	

54	Treatment of thymoma and prognostic factors: In regard to Zhu et al. (Int J Radiat Oncol Biol Phys 2004;60:1113-1119). <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 62, 942	4	1
53	Activation patterns of epidermal growth factor-receptor signaling in glioblastoma multiforme: in regard to Chakravarti et al. (Int J Radiat Oncol Biol Phys 2005;62:318-327). <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 62, 1253; author reply 1253	4	
52	Rationale for the use of trastuzumab in patients with cerebral metastases who previously receive trastuzumab-based therapy for metastatic breast cancer. <i>Breast</i> , 2005 , 14, 425	3.6	6
51	PTEN activation may contribute to exquisite antitumor response to trastuzumab. <i>Breast</i> , 2005 , 14, 175; author reply 176	3.6	
50	Cisplatin as a radiosensitizer in the treatment of locally advanced head and neck cancer. <i>Oral Oncology</i> , 2005 , 41, 435	4.4	2
49	Association between cyclooxygenase and epidermal growth factor receptor pathways in non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005 , 130, 1484-5; author reply 1485	1.5	
48	Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients. <i>Head and Neck</i> , 2005 , 27, 15-21	4.2	29
47	Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial. <i>Cancer</i> , 2005 , 104, 2033-4; author reply 2034	6.4	7
46	Nanobacteria and breast implant capsule contracture and calcification: a hypothesis. <i>Aesthetic Plastic Surgery</i> , 2005 , 29, 582	2	5
45	Is there an association between high heparanase level and osteoporosis risk in breast cancer patients without clinical evidence of bone metastases?. <i>Osteoporosis International</i> , 2005 , 16, 2195-6	5.3	1
44	Endogenous estrogen levels, bone mineral density and estrogen receptor status in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005 , 89, 213	4.4	
43	Possible role of CXCR4-mediated chemotaxis in breast cancer patients with central nervous system metastases. <i>Breast Cancer Research and Treatment</i> , 2005 , 89, 317	4.4	1
42	Re: Cetuximab therapy and symptomatic hypomagnesemia. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1791-2	9.7	9
41	Cyclooxygenase inhibitors may be more effective in hormone-dependent endometrial cancers: interaction between cyclooxygenase and aromatase. <i>Annals of Oncology</i> , 2005 , 16, 1559	10.3	
40	Obesity may decrease the amenorrhea associated with chemotherapy in premenopausal breast cancer patients. <i>Annals of Oncology</i> , 2005 , 16, 333; author reply 333-4	10.3	1
39	Heparin and CXCL12 dimerization. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7248	2.2	10
38	Heparanase activity and bone loss in postmenopausal breast cancer patients. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8916-7; author reply 8917-8	2.2	2
37	CA125 Nadir values as a prognostic factor in epithelial ovarian cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2435-6; author reply 2436	2.2	2

36	Targeted therapy for targeted patients: trastuzumab in adjuvant treatment of non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1325; author reply 1326-7	2.2	3
35	The role of insulin-like growth factor-I receptor in the development of Herceptin resistance. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1136; author reply 1136	6.1	1
34	Adjuvant chemotherapy in patients 80-89 years of age with non-small cell lung cancer. <i>European Journal of Cardio-thoracic Surgery</i> , 2005 , 28, 911-2; author reply 912	3	
33	Hormone receptor status in patients with breast cancer and liver metastases treated with laser-induced intersititial thermotherapy. <i>Radiology</i> , 2005 , 235, 339; author reply 339-40	20.5	2
32	Multiple myeloma. <i>New England Journal of Medicine</i> , 2005 , 352, 840-1; author reply 840-1	59.2	1
31	Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1044; author reply 1044-5	2.2	33
30	The risk of distant metastases in patients with non-small cell lung cancer (NSCLC) with cytologically proven malignant pleural effusion, stage IIIB: A retrospective analysis. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9568-9568	2.2	2
29	Hormone receptor status of primary tumor as a prognostic factor in patients with liver metastases from breast cancer treated with transcatheter arterial chemoembolization. <i>World Journal of Gastroenterology</i> , 2005 , 11, 7057	5.6	
28	Uracil-tegafur in early-stage lung cancer. <i>New England Journal of Medicine</i> , 2004 , 351, 713-4; author reply 713-4	59.2	
27	MRI in breast cancer. <i>New England Journal of Medicine</i> , 2004 , 351, 2235-6; author reply 2235-6	59.2	
26	Re: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 558-9	9.7	3
25	Free circulating DNA: good as a diagnostic marker in lung cancer?. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3201-2; author reply 3202	2.2	4
24	Cyclooxygenase-2 inhibitor and cisplatin combination as a radiosensitizer in the treatment of head and neck cancer patients. <i>Annals of Oncology</i> , 2004 , 15, 1444-5	10.3	2
23	Pamidronate, hypocalcemia, and calcium and vitamin D supplementation. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2035; author reply 2035	2.2	
22	Unusual abdominal tumors, case 3. Primary omental T-cell lymphoblastic lymphoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1522-3	2.2	1
21	Late local recurrences in a randomized trial comparing conservative treatment with total mastectomy in early breast cancer patients: the impact of receptor status on local relapse. <i>Annals of Oncology</i> , 2004 , 15, 990; author reply 991	10.3	
20	The field of radiation therapy may effect health-related quality of life in patients with operable breast cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1765; author reply 1765-6	2.2	1
19	Obesity may be a independent prognostic factor in premenopausal breast cancer patients. <i>Breast</i> , 2004 , 13, 536	3.6	

18	Possible association between c-erbB-2 and human papillomavirus-16 in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2004 , 87, 109	4.4	1
17	Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with Cisplatin-based chemotherapy. <i>Medical Oncology</i> , 2004 , 21, 211-5	3.7	15
16	Isolated hyperbilirubinemia following standard dose cytosine arabinoside in a patient with relapsed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2004 , 75, 263-4	7.1	8
15	Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. <i>Cancer</i> , 2004 , 100, 1768-9; author reply 1769	6.4	2
14	High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. <i>Cancer</i> , 2004 , 101, 1101-2; author reply 1102-3	6.4	2
13	Addition of granulocyte-colony stimulating factor (G-CSF) may further increase chemosensitive state in premenopausal node-positive breast cancer patients with induced angiogenesis after surgery. <i>Breast Cancer Research</i> , 2004 , 6, E14	8.3	
12	Addition of granulocyte-colony stimulating factor (G-CSF) to adjuvant treatment may increase survival in patients with operable breast cancer: interaction of G-CSF with dormant micrometastatic breast cancer cells. <i>Medical Hypotheses</i> , 2004 , 63, 56-8	3.8	8
11	Adjuvant targeted therapy with trastuzumab may decrease metastatic capacity in specific group of oropharyngeal cancer patients: downregulation of E-cadherin-catenin complex by cooperative effect of erbB-2 and human papillomavirus type 16 E6/E7 protooncogenes. <i>Medical Hypotheses</i> , 2004 , 63, 67-8	3.8	3
10	DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients. <i>Medical Hypotheses</i> , 2004 , 63, 684-7	3.8	17
9	Possible interaction between activator protein-1 and proto-oncogene B-cell lymphoma gene 6 in breast cancer patients resistant to tamoxifen. <i>Medical Hypotheses</i> , 2004 , 63, 823-6	3.8	7
8	Calcium and vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis. <i>Medical Hypotheses</i> , 2004 , 63, 1010-3	3.8	8
7	Ifosfamide-doxorubicin combination in patients with locally recurrent or metastatic nasopharyngeal carcinoma pretreated with cisplatin based chemotherapy: Retrospective analysis of 21 patients. <i>Journal of Clinical Oncology</i> , 2004 , 22, 5603-5603	2.2	
6	Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4656; author reply 4657	2.2	
5	Pineal germ cell tumor metastasis via ventriculoperitoneal shunt. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002 , 25, 104-5	2.7	12
4	Hyper eosinophilia and metastatic anaplastic carcinoma of unknown primary. <i>Medical Oncology</i> , 2001 , 18, 285-8	3.7	5
3	Recurrent asymptomatic bradycardia episodes after cisplatin infusion. <i>Annals of Pharmacotherapy</i> , 2001 , 35, 641-2	2.9	21
2	Perianal infections in patients with leukemia: importance of the course of neutrophil count. <i>Diseases of the Colon and Rectum</i> , 1998 , 41, 81-5	3.1	41
1	Multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 1998 , 27, 165-7	7	5

